Literature DB >> 18980732

Do antidepressants really work? A clinicians' guide to evaluating the evidence.

Michael E Thase1.   

Abstract

Although antidepressants represent the cornerstone of medical management of major depressive disorder, several widely publicized recent developments have called into question the safety and effectiveness of the antidepressant medications. This article reviews the methods used to conduct studies of antidepressant efficacy, with particular focus on the research conducted by the pharmaceutical industry. It is concluded that the specific efficacy of antidepressant medications in contemporary, industry-sponsored, randomized, controlled trials is modest compared with that of medications in double-blind, placebo trials. Sources of bias and artifact that detract from these studies' validity and limit their interpretability are reviewed. It is also argued that these studies--which are primarily conducted to obtain regulatory approval, to introduce new medications, or to showcase particular advantages of newer drugs after regulatory approval--form an inadequate basis for an evidence-based medicine assessment of antidepressant effectiveness.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18980732     DOI: 10.1007/s11920-008-0078-2

Source DB:  PubMed          Journal:  Curr Psychiatry Rep        ISSN: 1523-3812            Impact factor:   5.285


  21 in total

1.  Use of placebo control groups in evaluating efficacy of treatment of unipolar major depression.

Authors:  A F Schatzberg; H C Kraemer
Journal:  Biol Psychiatry       Date:  2000-04-15       Impact factor: 13.382

Review 2.  Flawed meta-analyses comparing psychotherapy with pharmacotherapy.

Authors:  D F Klein
Journal:  Am J Psychiatry       Date:  2000-08       Impact factor: 18.112

3.  Effects of interrater reliability of psychopathologic assessment on power and sample size calculations in clinical trials.

Authors:  Matthias J Müller; Armin Szegedi
Journal:  J Clin Psychopharmacol       Date:  2002-06       Impact factor: 3.153

Review 4.  Size of treatment effects and their importance to clinical research and practice.

Authors:  Helena Chmura Kraemer; David J Kupfer
Journal:  Biol Psychiatry       Date:  2005-12-20       Impact factor: 13.382

5.  The revised warning for antidepressants and suicidality: unveiling the black box of statistical analyses.

Authors:  Andrew C Leon
Journal:  Am J Psychiatry       Date:  2007-12       Impact factor: 18.112

6.  The continuing unethical use of placebo controls.

Authors:  K J Rothman; K B Michels
Journal:  N Engl J Med       Date:  1994-08-11       Impact factor: 91.245

Review 7.  National Depressive and Manic-Depressive Association consensus statement on the use of placebo in clinical trials of mood disorders.

Authors:  Dennis S Charney; Charles B Nemeroff; Lydia Lewis; Sally K Laden; Jack M Gorman; Eugene M Laska; Michael Borenstein; Charles L Bowden; Arthur Caplan; Graham J Emslie; Dwight L Evans; Barbara Geller; Lenore E Grabowski; Jay Herson; Ned H Kalin; Paul E Keck; Irving Kirsch; K Ranga R Krishnan; David J Kupfer; Robert W Makuch; Franklin G Miller; Herbert Pardes; Robert Post; Mildred M Reynolds; Laura Roberts; Jerrold F Rosenbaum; Donald L Rosenstein; David R Rubinow; A John Rush; Neal D Ryan; Gary S Sachs; Alan F Schatzberg; Susan Solomon
Journal:  Arch Gen Psychiatry       Date:  2002-03

8.  Symptom reduction and suicide risk in patients treated with placebo in antidepressant clinical trials: an analysis of the Food and Drug Administration database.

Authors:  A Khan; H A Warner; W A Brown
Journal:  Arch Gen Psychiatry       Date:  2000-04

9.  Selective publication of antidepressant trials and its influence on apparent efficacy.

Authors:  Erick H Turner; Annette M Matthews; Eftihia Linardatos; Robert A Tell; Robert Rosenthal
Journal:  N Engl J Med       Date:  2008-01-17       Impact factor: 91.245

Review 10.  Comparing the methods used to compare antidepressants.

Authors:  Michael E Thase
Journal:  Psychopharmacol Bull       Date:  2002
View more
  8 in total

Review 1.  The small specific effects of antidepressants in clinical trials: what do they mean to psychiatrists?

Authors:  Michael E Thase
Journal:  Curr Psychiatry Rep       Date:  2011-12       Impact factor: 5.285

Review 2.  Prenatal antidepressant exposure: clinical and preclinical findings.

Authors:  Chase H Bourke; Zachary N Stowe; Michael J Owens
Journal:  Pharmacol Rev       Date:  2014-02-24       Impact factor: 25.468

3.  Ego defense mechanisms in COPD: impact on health-related quality of life and dyspnoea severity.

Authors:  Saulo C Albuquerque; Eduardo R Carvalho; Rebeka S Lopes; Higor S Marques; Danielle S Macêdo; Eanes D Pereira; Thomas N Hyphantis; Andre F Carvalho
Journal:  Qual Life Res       Date:  2011-03-15       Impact factor: 4.147

Review 4.  Coverage of mental health and substance misuse topics in the Cochrane review system.

Authors:  S Green-Hennessy
Journal:  Epidemiol Psychiatr Sci       Date:  2012-08-29       Impact factor: 6.892

5.  The efficacy of extended-release levomilnacipran in moderate to severe major depressive disorder: secondary and post-hoc analyses from a randomized, double-blind, placebo-controlled study.

Authors:  Stuart A Montgomery; Lucilla Mansuy; Adam C Ruth; Dayong Li; Carl Gommoll
Journal:  Int Clin Psychopharmacol       Date:  2014-01       Impact factor: 1.659

6.  Chronic citalopram administration causes a sustained suppression of serotonin synthesis in the mouse forebrain.

Authors:  Gerard Honig; Minke E Jongsma; Marieke C G van der Hart; Laurence H Tecott
Journal:  PLoS One       Date:  2009-08-27       Impact factor: 3.240

Review 7.  Neglected tropical diseases: survey and geometry of randomised evidence.

Authors:  Shanthi Kappagoda; John P A Ioannidis
Journal:  BMJ       Date:  2012-10-22

8.  Effects of levomilnacipran ER on fatigue symptoms associated with major depressive disorder.

Authors:  Marlene P Freeman; Maurizio Fava; Carl Gommoll; Changzheng Chen; William M Greenberg; Adam Ruth
Journal:  Int Clin Psychopharmacol       Date:  2016-03       Impact factor: 1.659

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.